Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders

@article{Kenney2007LongtermTO,
  title={Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders},
  author={Christopher Kenney and Christine Hunter and Joseph Jankovic},
  journal={Movement Disorders},
  year={2007},
  volume={22}
}
We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders. A retrospective chart review was performed on patients treated with TBZ between 1997 and 2004. Efficacy of TBZ was assessed by a 1‐ to 5‐point response scale (1 = marked reduction in abnormal movements, 5 = worsening). All adverse events (AEs) were captured according to their relationship with study drug. A total of 448 patients (42… 
Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study
TLDR
TBZ proved an effective and relatively well tolerated treatment in hyperkinetic disorders, with excellent results in HD, and was more common in OM dyskinesia, which may be related to higher age at TBZ initiation.
The Long-term Effect of Tetrabenazine in the Management of Huntington Disease
TLDR
Tetrabenazine was well tolerated and produced long-term improvement of motor symptoms in Huntington disease patients, although a slight reduction of benefit occurred during the course of treatment.
Comparison of Weight Gain in Treatments for Tourette Syndrome: Tetrabenazine Versus Neuroleptic Drugs
TLDR
Weight gain over time was compared in a group of pediatric tic patients taking only tetrabenazine with an age-matched group of tics taking only neuroleptic drugs.
Deutetrabenazine in the treatment of tardive dyskinesia.
TLDR
Two pivotal clinical trials provide evidence that deutetrabenazine dosed 24-48 mg/day effectively controlled involuntary movements according to rating scales, and interim results of a long-term open-label study show continued efficacy and good tolerability, even in combination with baseline dopamine receptor blocking agents.
The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
TLDR
AIMS and CGI-TD measures indicated sustained tardive dyskinesia improvement, with scores returning toward baseline after 4 weeks of valbenazine washout, and maintenance of treatment effect was apparent with both doses during this long-term study.
Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
  • D. Guay
  • Medicine, Psychology
    The American journal of geriatric pharmacotherapy
  • 2010
Tardive dyskinesia and other movement disorders secondary to aripiprazole
The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed to typical
Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
TLDR
Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way, however, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial.
Is History of Depression a Contraindication to Treatment With Tetrabenazine?
TLDR
Depression, an adverse event of TBZ, is more likely to occur or worsen in patients with a preexisting history of depression, compared to those with a nonexistence of depression.
...
...

References

SHOWING 1-10 OF 51 REFERENCES
Long-term effects of tetrabenazine in hyperkinetic movement disorders
TLDR
TBZ is an effective and safe drug for the treatment of a variety of hyperkinetic movement disorders and in contrast to typical neuroleptics, TBZ has not been demonstrated to cause tardive dyskinesia.
Tetrabenazine Treatment in Movement Disorders
TLDR
It is concluded that TBZ is a moderately effective treatment of a large variety of hyperkinetic movement disorders, with excellent effects in a subgroup with chorea and facial dystonia/dyskinesias.
Tetrabenazine Treatment for Huntington's Disease-Associated Chorea
TLDR
TBZ was well tolerated and resulted in a significant improvement in modified AIMS scores in HD patients, which support the use of TBZ for chorea in patients with HD.
Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study
TLDR
Tetrabenazine is a useful and safe therapeutic agent in some patients with hyperkinetic movement disorders and shows marked improvement in one patient with Huntington disease and two patients with congenital choreoathetosis.
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
TLDR
Tetrabenazine (TBZ), at adjusted dosages of up to 100 mg/day, effectively lessens chorea in ambulatory patients with Huntington disease and should be dosed individually based on ongoing assessment of possible adverse side effects.
Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.
TLDR
Tetrabenazine was well tolerated and resulted in significant improvements in AIMS scores for patients with refractory tardive dyskinesia, particularly on the motor subset of the modified Abnormal Involuntary Movement Scale.
Is History of Depression a Contraindication to Treatment With Tetrabenazine?
TLDR
Depression, an adverse event of TBZ, is more likely to occur or worsen in patients with a preexisting history of depression, compared to those with a nonexistence of depression.
Extrapyramidal side effects with atypical neuroleptics in bipolar disorder
Tardive dyskinesia.
TLDR
An ongoing prospective study suggests that the annual incidence of tardive dyskinesia in patients over age 45 is over 30 percent, and likely risk factors include female gender, mood disorders, "organic" brain dysfunction or damage, diabetes mellitus, and early extrapyramidal side effects.
A therapeutic approach to tardive dyskinesia.
  • S. Fahn
  • Medicine, Psychology
    The Journal of clinical psychiatry
  • 1985
TLDR
Treatment with reserpine and discontinuance of antipsychotic drugs was useful for patients with severe symptoms of tardive dyskinesia or akathisia; complete remission with elimination of all drugs was achieved in 4 of 19 treated patients, without recurrence of symptoms.
...
...